Saturday 17 October 2026
Export CVKD’s income statement to Excel — free account
Cadrenal Therapeutics, Inc.
CVKD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 39.0% and free cash flow grew 26.2%, each against the same quarter a year earlier.
1.09
0.12
+12.37%
Follow CVKD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(468.03%) | (260.11%) | (300.59%) | (275.16%) | |
| (328.18%) | (183.21%) | (219.84%) | (199.59%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (427.54%) | |
Return on Tangible Assets |
(526.43%) | (483.72%) | (662.35%) | (282.28%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(5.79) | (6.32) | (4.55) | (3.49) | |
Free Cash Flow |
(11.83) | (12.61) | (10.96) | (10.16) | |
Capital Expenditures |
(0.01) | (0.01) | — | 0.00 | |
| Other line items | |||||
Cash ROIC |
(179.44%) | (186.86%) | (266.86%) | (156.84%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 0.95 | 0.92 | 0.88 | |
Depreciation/Fixed assets |
1.18 | 1.33 | 0.43 | 0.78 | |
Capex/Depreciation |
(1.73) | (0.74) | 0.00 | (0.19) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.78) | (6.32) | (4.55) | (3.49) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates